Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,196 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Comparator: Control group Clear all
Completed Phase 2 Interventional Results available

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age

NCT04405180
View directory record Official record
Conditions
Aging, Sedentary Lifestyle, Frailty
Interventions
Placebos, 20mg sodium nitrite tid
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
70 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

NCT00103727
View directory record Official record
Conditions
Schizophrenia
Interventions
Talnetant, placebo, risperidone
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
22
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 17, 2026, 5:45 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

NCT07092618
View directory record Official record
Conditions
Longevity, GLP-1, Geroscience, Aging
Interventions
Metformin, Rapamycin, Naltrexone, Vitamin C
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Not applicable Interventional

Lidocaine Patch for Neck Pain

NCT04378959
View directory record Official record
Conditions
Neck Pain, Neck Pain, Posterior
Interventions
Lidocaine patch, Placebo patch
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 4 Interventional

Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension

NCT00419796
View directory record Official record
Conditions
Osteoarthritis With Controlled Hypertension
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Sep 17, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

NCT02484703
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, RO5186582
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 17, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional

Nicotinamide Riboside Clinical Trial for GWI

NCT05243290
View directory record Official record
Conditions
Gulf War Illness
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Roskamp Institute Inc.
Other
Eligibility
47 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496
View directory record Official record
Conditions
Endocrine Tumors
Interventions
lanreotide (Autogel formulation), Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase

NCT01042262
View directory record Official record
Conditions
Oxidative Stress, Fetal Distress
Interventions
Oxygen, Placebo
Other
Lead sponsor
George Washington University
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2010 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

RN624 In Adult Patients With Chronic Low Back Pain

NCT00584870
View directory record Official record
Conditions
Low Back Pain
Interventions
Naproxen, Placebo, PF-04383119 (RN624)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 17, 2026, 5:45 PM EDT
Recruiting Phase 3 Interventional

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320
View directory record Official record
Conditions
Episodic Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 5:45 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

NCT07536282
View directory record Official record
Conditions
Persistent HPV16 Infection
Interventions
NWRD09, Placebo
Biological
Lead sponsor
Newish Biotech (Wuxi) Co., Ltd.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT01457924
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS-SR 50 mg, DVS-SR 100 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Beverly Hills, California • Northridge, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 17, 2026, 5:45 PM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Port Charlotte, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

NCT02949388
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 17, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional

Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture

NCT06571110
View directory record Official record
Conditions
Fibromyalgia
Interventions
Traditional Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

NCT01414920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
80
States / cities
Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of ALK-001 in Geographic Atrophy

NCT03845582
View directory record Official record
Conditions
Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
Interventions
ALK-001 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 2 Interventional

The Lived Experiences Measured Using Rings Pilot Study

NCT05841979
View directory record Official record
Conditions
Depression, Stress, Sleep, Anxiety
Interventions
Moodlifters, Physical Activity, Nature Experiences
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 25 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Not applicable Interventional

TENS Unit To Decrease Pain After Laminaria Insertion

NCT06529003
View directory record Official record
Conditions
Second Trimester Abortion
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS) unit, Placebo
Device
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers

NCT03596697
View directory record Official record
Conditions
Hepatitis B, Infectious Disease, Liver Diseases
Interventions
CRV431, Placebo, TDF
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tempe, Arizona • Lincoln, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 17, 2026, 5:45 PM EDT